Icade Toekomstige groei
Future criteriumcontroles 3/6
Icade zal naar verwachting groeien in winst en omzet met respectievelijk 86.7% en 1.6% per jaar. De winst per aandeel zal naar verwachting groeien met 94.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 5.6% zijn.
Belangrijke informatie
86.7%
Groei van de winst
94.65%
Groei van de winst per aandeel
| REITs winstgroei | 11.5% |
| Inkomstengroei | 1.6% |
| Toekomstig rendement op eigen vermogen | 5.60% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 06 May 2026 |
Recente toekomstige groei-updates
Recent updates
ICAD: Slower Healthcare Disposal And Halted Special Payouts Will Pressure Shares
Analysts have reduced their price target on Icade from €30 to €25, citing expectations that the healthcare business disposal could take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts are flagging a more cautious stance on Icade, with recent research pointing to timing and payout uncertainties that weigh on sentiment.ICAD: Slower Healthcare Disposal And Lost Special Dividends Will Pressure Shares
Analysts have trimmed their price target for Icade to €25 from €30, reflecting expectations that the planned disposal of the healthcare business may take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts have shifted to a more cautious stance on Icade, with the rating cut to Equal Weight from Overweight and the price target moved to €25 from €30.
ICAD: Slower Healthcare Disposal And Missing Special Dividends Will Shape Fair Outlook
Narrative Update The analyst price target for Icade has been trimmed to €21.35 from €21.54. This reflects a more cautious stance from analysts after recent downgrades and expectations that healthcare asset disposals and potential special dividends may take longer to play out.
ICAD: Slower Healthcare Exit And Reset Distributions Will Support Future Repricing
Analysts have trimmed their fair value estimate for Icade to about €29.91 from €31.29, echoing recent price target cuts, such as the move from €30 to €25, as they factor in a longer timeline for healthcare asset disposals and the absence of expected special dividends. Analyst Commentary The recent research updates on Icade point to a more cautious stance as analysts reassess how quickly the group can execute on its healthcare disposals and how generous future shareholder returns might be.ICAD: Slower Healthcare Disposals And Lost Special Dividends Will Shape Fairly Valued Outlook
Analysts have modestly trimmed their fair value estimate for Icade from €22.03 to about €21.54. This reflects updated views on slower progress on healthcare disposals, a higher required discount rate and the removal of assumed special dividends after recent downgrades and price target cuts on the stock.ICAD: Higher Office Risk Premium Will Set Stage For Future Repricing
Analysts have reduced their fair value estimate for Icade from about €36.67 to about €31.29, reflecting a higher assumed discount rate and lower profit margin expectations following recent rating cuts and a lower €18 Street price target. Analyst Commentary Recent rating actions on Icade have leaned cautious, with cuts to both recommendations and price targets that feed into the lower fair value estimate.ICAD: Office Risk Repricing And Downgrades Will Shape Fairly Valued Outlook
Analysts have trimmed their fair value estimate for Icade from €23.33 to €22.03. This reflects a slightly higher discount rate, a modestly lower profit margin outlook and recent downgrades that cite a higher perceived equity risk premium in offices.ICAD: Office Risk Repricing And Downgrades Will Shape Future Share Performance
Analysts have trimmed their fair value estimate for Icade from about €23.46 to roughly €23.33, citing slightly higher required returns, more cautious assumptions on revenue growth and profit margins, and recent Street downgrades, including a cut in one price target from €25 to €18. Analyst Commentary Bullish Takeaways Bullish analysts may see the recent pullback in fair value and price targets as already reflecting higher equity risk premiums in offices, which can limit further downside if execution on existing projects is steady.ICAD: Office Downgrades And Higher Risk Premium Will Pressure Shares
Analysts have trimmed their price expectations for Icade to around €14.60, reflecting recent rating downgrades and a higher equity risk premium for office assets. This has been incorporated into updated assumptions for revenue growth, profit margins and future P/E levels.ICAD: Office Risk Repricing Will Shape Margins And Share Performance
Analysts have lowered their price target on Icade from EUR 25 to EUR 18. This reflects a higher perceived equity risk in offices, alongside slightly faster expected revenue growth but weaker profit margins and a higher valuation multiple.ICAD: Office Weakness And Higher Equity Risk Will Pressure Shares
Analysts have cut their price target on Icade from EUR 17.80 to EUR 14.60, reflecting a lower revenue growth outlook and higher perceived equity risk in offices, even as profit margins are expected to improve. Analyst Commentary Bearish analysts have recently shifted their stance on Icade, highlighting a weaker outlook for office assets and increasing caution around the company’s equity risk profile.
Pulse Building Lease With Seine-Saint-Denis Will Boost Portfolio Strength
Improved rental growth expected from the lease agreement and focus on prime locations may enhance revenue stability.A Look At Icade's (EPA:ICAD) Share Price Returns
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...How Did Icade SA's (EPA:ICAD) 8.0% ROE Fare Against The Industry?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...What Type Of Shareholders Make Up Icade SA's (EPA:ICAD) Share Registry?
If you want to know who really controls Icade SA ( EPA:ICAD ), then you'll have to look at the makeup of its share...Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 1,409 | 244 | 111 | 181 | 4 |
| 12/31/2027 | 1,328 | 154 | 831 | 208 | 5 |
| 12/31/2026 | 1,304 | 47 | 962 | 253 | 5 |
| 12/31/2025 | 1,337 | -123 | 300 | 300 | N/A |
| 9/30/2025 | 1,338 | -155 | 314 | 314 | N/A |
| 6/30/2025 | 1,339 | -187 | 328 | 328 | N/A |
| 3/31/2025 | 1,376 | -231 | 347 | 347 | N/A |
| 12/31/2024 | 1,412 | -275 | 366 | 366 | N/A |
| 9/30/2024 | 1,468 | -614 | 316 | 316 | N/A |
| 6/30/2024 | 1,523 | -953 | 265 | 265 | N/A |
| 3/31/2024 | 1,524 | -1,121 | 251 | 251 | N/A |
| 12/31/2023 | 1,525 | -1,289 | 238 | 238 | N/A |
| 9/30/2023 | 1,494 | -1,116 | 317 | 317 | N/A |
| 6/30/2023 | 1,464 | -944 | 397 | 397 | N/A |
| 3/31/2023 | 1,467 | -657 | 319 | 319 | N/A |
| 12/31/2022 | 1,469 | -370 | 242 | 242 | N/A |
| 9/30/2022 | 1,496 | -61 | N/A | N/A | N/A |
| 6/30/2022 | 1,524 | 249 | 547 | 224 | N/A |
| 3/31/2022 | 1,586 | 324 | 538 | 377 | N/A |
| 12/31/2021 | 1,648 | 399 | 529 | 529 | N/A |
| 6/30/2021 | 1,640 | 280 | -51 | 600 | N/A |
| 3/31/2021 | 1,534 | 178 | 34 | 625 | N/A |
| 12/31/2020 | 1,429 | 76 | 120 | 650 | N/A |
| 6/30/2020 | 1,458 | 259 | -233 | 453 | N/A |
| 3/31/2020 | 1,485 | 278 | -325 | 411 | N/A |
| 12/31/2019 | 1,512 | 298 | -417 | 369 | N/A |
| 9/30/2019 | 1,587 | 235 | N/A | 358 | N/A |
| 6/30/2019 | 1,662 | 173 | N/A | 346 | N/A |
| 3/31/2019 | 1,717 | 165 | N/A | 351 | N/A |
| 12/31/2018 | 1,773 | 156 | N/A | 356 | N/A |
| 9/30/2018 | 1,714 | 137 | N/A | 372 | N/A |
| 6/30/2018 | 1,655 | 118 | N/A | 387 | N/A |
| 3/31/2018 | 1,642 | 142 | N/A | 362 | N/A |
| 12/31/2017 | 1,629 | 165 | N/A | 337 | N/A |
| 6/30/2017 | 1,596 | 106 | N/A | 255 | N/A |
| 3/31/2017 | 1,542 | 75 | N/A | 235 | N/A |
| 12/31/2016 | 1,487 | 45 | N/A | 215 | N/A |
| 6/30/2016 | 1,391 | -101 | N/A | 309 | N/A |
| 3/31/2016 | 1,411 | -144 | N/A | 307 | N/A |
| 12/31/2015 | 1,431 | -187 | N/A | 305 | N/A |
| 6/30/2015 | 1,649 | 82 | N/A | 526 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Er wordt voorspeld dat ICAD de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.5% ).
Winst versus markt: Er wordt verwacht dat ICAD de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.
Hoge groeiwinsten: Er wordt verwacht dat ICAD binnen 3 jaar winstgevend zal worden.
Omzet versus markt: De omzet van ICAD ( 1.6% per jaar) zal naar verwachting langzamer groeien dan de markt French ( 5.6% per jaar).
Hoge groei-inkomsten: De omzet van ICAD ( 1.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen ICAD zal naar verwachting over 3 jaar laag zijn ( 5.6 %).
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/22 11:48 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Icade wordt gevolgd door 21 analisten. 11 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Celine Huynh | Barclays |
| Paul May | Barclays |
| Celine Huynh | Barclays |